Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at ASH19

— Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma —

— All Oral Regimen of Once-Weekly Selinexor with Revlimid® and Low Dose Dexamethasone Achieves High Response Rates in Patients with Newly Diagnosed Multiple Myeloma —

— STORM Study Patients Treated with Selinexor Achieved Survival Advantage Over Matched Patients from the MAMMOTH Study Who Were Treated with Other Anti-Myeloma Agents —

— Single-Agent Oral Eltanexor Shows Encouraging Activity in Elderly Patients with Higher-Risk Myelodysplastic Syndrome —

https://www.marketscreener.com/KARYOPHARM-THERAPEUTICS-I-14825950/news/Karyopharm-Presents-XPOVIO-Selinexor-and-Eltanexor-Data-at-the-American-Society-of-Hematology-201-29698409/